Inactive Instrument

Actelion Share Price London S.E.

Equities

CH0010532478

Biotechnology & Medical Research

Chart Actelion

Duration

Period

Style

Latest news about Actelion

Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	31/17/31	RE
Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	19/17/19	RE
Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	19/17/19	RE
Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	09/17/09	RE
Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	09/17/09	RE
Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	09/17/09	RE
Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	22/17/22	RE
Actelion : Johnson & Johnson offers EU concessions over Actelion deal	18/17/18	RE
Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	20/17/20	RE
Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	18/17/18	RE
Actelion : shareholders back R&D spinoff, keep J&J deal on track	05/17/05	RE
Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	31/17/31	RE
Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	23/17/23	RE
Bristol Myers Squibb : Icahn buys Bristol-Myers shares, adding to activist pressure	22/17/22	RE
Actelion : How Sanofi lost out to J&J in $30 billion battle for Actelion	16/17/16	RE

Analyst Recommendations on Actelion

Dollar's post-Fed rally pauses, U.S. stocks end lower	17/16/17	RE
Actelion : raises guidance for third time this year on strong PAH sales	20/16/20	RE

More recommendations

Press releases Actelion

Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	06/20/06	AQ
Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	31/17/31	GL
Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	30/17/30	GL
Actelion : Johnson & Johnson Completes Acquisition of Actelion	16/17/16	GL
Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	16/17/16	PU

More press releases

News in other languages on Actelion

Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR	29/18/29
Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR	29/18/29
Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie	22/18/22
GNW-News: Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	31/17/31
Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	31/17/31

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	13TCr
ARGENX SE	+25.24%	2.77TCr
BIONTECH SE	-20.17%	2.03TCr
GENMAB A/S	-16.66%	1.68TCr
BEIGENE, LTD.	-18.07%	1.56TCr
WUXI APPTEC CO., LTD.	-47.70%	1.46TCr
NEUROCRINE BIOSCIENCES, INC.	+11.92%	1.48TCr
SAREPTA THERAPEUTICS, INC.	+58.32%	1.44TCr
INSMED INCORPORATED	+149.98%	1.25TCr

Bio Therapeutic Drugs

Our Free Content Help you Secure and Increase the Performance of Your Investments

Secure my Investments

fermer